Conscious Investing in Psychedelics

Join us for a webinar on August 18, 2021.
  • Wednesday, August 18, 2021
  • 11am PT / 2pm ET
  • 60 minutes

The growth of the psychedelic industry is usually compared to how medical cannabis burst onto the scene, but things appear to be moving with even more urgency for psychedelics. The FDA recently labeled Psilocybin therapy as a “breakthrough therapy,” and the Veteran’s Administration has approved the use of psychedelic medicine for soldiers to treat their PTSD.

The “Coming Golden Age of Psychedelic Medicine” is upon us. Join us to learn how you can become a conscious investor of the psychedelic industry!

During our next webinar, Arcview Capital, DealMaker, and Ei.Ventures will share:

  • The basics of the Reg A+ structure, and how it allows both non-accredited and accredited investors to buy shares.
  • The psychedelic revolution and how alternative medicines are becoming mainstream.
  • How you can invest in Ei.Ventures’ mission to bring the healing power of plant medicines to the world.


Brian MacDonald
Head of Intermediary Sales & Fund Distribution, Arcview Capital


Rebecca Kacaba,
Chief Executive Officer & Co-Founder of DealMaker

Cecil Robles,
Co-Founder and Chief Strategy Officer of Ei. Ventures

Dr. Linda Strause Ph.D,
Director of Clinical Development of Ei. Ventures

Tyler Strause,
Product Development of Ei. Ventures